BIOGEN INC. (BIIB)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$221.56
+4.24%
Investingg Score
53.8 / 100
Hold
Business overview
- Gross margin is 75.7%
- Free cash flow margin stands at 20.7%
- Operating margin is Data unavailable.
These figures indicate solid core profitability and robust cash generation, though lack of operating margin data introduces uncertainty regarding overall operational efficiency.
Financial health
- Free cash flow yield is 6.3%
- Balance sheet pillar score is 64 out of 100
- Risk pillar score is 90 out of 100
These metrics suggest a stable financial foundation with strong risk management characteristics, though broader balance sheet liabilities require continuous monitoring.
- Gross Margin
- 75.7%
- Operating Margin
- Data unavailable
- Current Ratio
- 2.7x
- Debt / Equity
- 0.34
- Free Cash Flow (TTM)
- $2.1B
- Interest Coverage
- Data unavailable
Valuation
- Price-to-earnings ratio is 19.58
- Forward price-to-earnings ratio is 14.02
- Price-to-sales ratio is 3.22
These ratios indicate that the stock is moderately valued relative to its current earnings and sales, with expected improvement in forward earnings reducing the forward multiple.
- P/E (TTM)
- 19.6x
- Forward P/E
- 14.0x
- Price / Sales
- 3.2x
- EV / EBITDA
- Data unavailable
- FCF Yield
- 6.3%
Key risks
- Year-over-year earnings per share growth has declined by 21.4%.
- Revenue growth year-over-year remains constrained at a low 2.2%.
- Operating margin information is completely unavailable.
Market cap $32.5B · data as of 2026-08-19
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze BIIB with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.